Gelesis, maker of weight-loss pill Plenity, files for Chapter 7 liquidation

Gelesis Holdings, Inc. and its two U.S. subsidiaries ceased operations and filed for Chapter 7 liquidation on October 30, 2023, in the U.S. Bankruptcy Court for the District of Delaware, Case No. 23-11787 ^[1][2]. The Boston-based company sold Plenity, a prescription weight-loss capsule taken by mouth and dispensed through telehealth consultations ^[2].

Chapter 7 is a liquidation, not a reorganization. A Chapter 7 trustee will be appointed by the court and will take control of the company's assets and liabilities, "effectively eliminating the authority and powers of the Board of Directors of the Company and its executive officers to act on behalf of the Company," according to the company's filing ^[1]. The assets are then liquidated and claims paid under the Bankruptcy Code ^[1].

In its petition, the company listed assets in the range of $50 million to $100 million and liabilities of $44.34 million ^[2]. It is represented by Kenneth Listwak of Troutman Pepper Hamilton Sanders LLP ^[2].

The filing came with the immediate departure of the company's leadership. Chief Executive Officer Yishai Zohar — who also held the titles of interim principal financial officer, principal accounting officer, treasurer, chief compliance officer and corporate secretary — and Chief Operating Officer and Chief Commercial Officer David Pass resigned effective October 30, 2023. As of that date, the company reported it had no officers, consultants or employees ^[1]. Six directors, including chair Paul Fonteyne and Zohar, also resigned, leaving no current members of the board ^[1].

Court records reported after the filing show the case moving through administration and sale. A motion for joint administration of the affiliated cases was filed January 30, 2024, and approved February 1, 2024. A motion for asset sale was filed April 9, 2024, and bidding procedures were approved April 19, 2024. A notice of successful bidder was filed May 8, 2024, and the motion for asset sale was approved May 23, 2024 ^[2].

Why it matters for patients

Gelesis described Plenity as an orally administered capsule, available by prescription after a telehealth consultation with a physician trained in weight management support, with free follow-up visits as needed ^[2]. It was not a GLP-1 medication. The company described its focus as superabsorbent hydrogel therapeutics for conditions including excess weight and type 2 diabetes ^[2].

For anyone who was using or considering Plenity, the bankruptcy filing does not address what happens to the product. The filings do not say whether Plenity is still being manufactured, prescribed or shipped, and they do not describe what happens to existing prescriptions or to patients who were being treated. Whether the product or brand was included in the 2024 asset sale, and what the buyer intends to do with it, has not been reported ^[1][2].

The case also points to a distinction that can be easy to miss: having a commercially available, prescribed product is separate from the financial health of the company that sells it. The bankruptcy record concerns Gelesis's finances and corporate structure. It does not describe any regulatory action involving Plenity, and it does not state that the product was withdrawn for safety or effectiveness reasons ^[1][2]. It also does not contain guidance for patients currently taking the product, and it does not address individual care.

What happens next

The docket items reported in the case are dated. Joint administration was approved February 1, 2024, a successful bidder was identified on May 8, 2024, and the asset sale was approved May 23, 2024 ^[2]. What the buyer plans to do with the acquired assets, including whether Plenity returns to or stays on the U.S. market, has not been disclosed ^[2].

Whether Gelesis or its product line continues in any form, and whether patients who want Plenity can still fill a prescription, has not been reported.